Pharmesis International Ltd. 22nd AGM: Key Highlights and Shareholder Updates

Overview

Pharmesis International Ltd. held its 22nd Annual General Meeting (AGM) on 29 April 2026 at its Singapore headquarters. The meeting was chaired by Mr. Chew Heng Ching, Non-Independent Non-Executive Chairman. Other key Board members, company officers, auditors from Ernst & Young LLP, and representatives from Tricor Singapore Pte. Ltd. were present, with some Directors participating electronically.

Key Resolutions Passed

1. Adoption of FY2025 Financial Statements:
   • Shareholders unanimously approved the Directors’ Statement and Audited Financial Statements for the financial year ended 31 December 2025, along with the Auditors’ Report.
   • This vote of confidence signals continued stability and transparency in Pharmesis’s financial reporting.
2. Re-election of Key Directors:
   • Mr. Wu Xuedan was re-elected as Executive Director and CEO.
   • Mr. Seow Yong Teng was re-elected as Independent Non-Executive Director and remains Chairman of the Audit, Nominating, and Remuneration Committees.
   • Leadership continuity is often viewed positively by the market, as it provides strategic stability and ongoing corporate governance strength.
3. Directors’ Fees Approved:
   • Shareholders approved Directors’ fees of S\$92,000 for FY2026, payable quarterly in arrears.
   • Stable or increasing director remuneration can reflect confidence in management and board performance.
4. Re-appointment of Auditors:
   • Ernst & Young LLP was re-appointed as Auditors for FY2026, with Directors authorized to fix their remuneration.
   • Continued engagement with a Big Four audit firm underlines robust internal controls and external accountability, reassuring investors.
5. Authority to Allot and Issue Shares:
   • Shareholders granted the Board authority to allot and issue new shares up to 50% of the company’s issued share capital (excluding treasury shares and subsidiary holdings). Up to 20% can be issued on a non-pro-rata basis.
   • This resolution provides Pharmesis with strategic financial flexibility to raise capital for expansion, M&A, or other corporate actions, which could be both an opportunity and a risk for shareholders. Any actual capital raising or dilution event could significantly impact share value and warrants close monitoring.

Voting Results

• All resolutions were passed with 100% approval from the 12,783,000 shares represented at the meeting. No votes were cast against any resolution, reflecting strong shareholder support for the management and Board’s proposals.

Operational and Procedural Highlights

• There were no written questions from shareholders submitted prior to the AGM, nor were there any raised during the meeting, indicating broad satisfaction or lack of significant controversy over company matters.
• Polling procedures were managed by independent agents and scrutineers, ensuring transparency and compliance with SGX Listing Manual requirements.

Potential Price-Sensitive Issues

• Share Issuance Mandate: The renewed authority for the Board to issue up to 50% of share capital (with 20% non-pro-rata) is the most potentially price-sensitive event from the meeting. This could lead to share dilution if the mandate is exercised, or provide growth capital for strategic initiatives. Investors should monitor any future announcements related to new share issuances, as these could impact the share price—either positively (if proceeds are used for value-accretive purposes) or negatively (if dilution is not compensated by growth).
• Leadership Continuity: The unanimous re-election of key Directors and the appointment of Ernst & Young LLP as external auditor may reassure investors regarding stability and corporate governance, potentially supporting the share price.

Conclusion

The AGM concluded smoothly, with all resolutions carried unanimously and no dissent or controversy. Shareholders should monitor the company for any subsequent actions regarding share issuance, as well as ongoing performance and developments from the Board and Management.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making investment decisions.

法玛西斯国际有限公司第22届年度股东大会：要点与股东更新

概述

法玛西斯国际有限公司于2026年4月29日在新加坡总部召开了第22届年度股东大会（AGM）。会议由公司非独立非执行主席周恒清先生主持，其他董事会成员、公司财务主管、安永会计师事务所（Ernst & Young LLP）及Tricor Singapore Pte. Ltd.代表也出席了会议，部分董事通过电子方式参加。

通过的重要决议

1. 接纳2025财年财务报表：
   • 股东一致通过接纳截至2025年12月31日的董事声明、经审计财务报表及审计报告。
   • 此举显示公司财务报告的稳健和透明，增强了投资者信心。
2. 关键董事连任：
   • 吴学丹先生连任执行董事兼首席执行官。
   • 萧永腾先生连任独立非执行董事，并继续担任审计、提名及薪酬委员会主席。
   • 董事层的连续性通常被市场视为积极信号，确保公司战略和治理的稳定。
3. 董事薪酬获批：
   • 股东批准2026财年董事薪酬为92,000新元，按季后结算。
   • 董事薪酬的稳定或提升反映了对管理层和董事会表现的信心。
4. 审计师连任：
   • 安永会计师事务所（Ernst & Young LLP）连任2026财年的公司审计师，董事会有权决定其报酬。
   • 与四大会计师事务所的持续合作体现了公司坚实的内部控制和外部监督，有利于投资者信心。
5. 发行新股授权：
   • 股东授权董事会可根据公司已发行股本（不包括库存股和子公司持股）最多50%额度发行新股，其中最多20%可非按比例配售。
   • 此项授权为公司未来资本运作、扩张或并购等战略安排提供了灵活性。若公司实际行使该权力进行配股或定向增发，可能带来股本稀释或资本扩张，对股价产生重大影响，需投资者密切关注后续公告。

投票结果

• 所有议案均获出席的12,783,000股代表100%赞成，无反对票，显示股东对董事会高度支持。

会议程序与运作

• 会前及会议期间均无股东以书面或现场提问，显示公司运营平稳，未引发重大争议。
• 投票流程由独立机构和监票人负责，确保合规与透明。

潜在影响股价的事项

• 新股发行授权： 董事会获授权最多发行50%股本（其中20%可非按比例），是本次大会最具潜在影响力的事项。若公司行使该权力，可能导致股本稀释或为战略增长提供资金，投资者应密切关注相关新股发行公告，因其可能正面（如资金用于增值项目）或负面（如单纯稀释）影响股价。
• 管理层连续性： 关键董事连任及安永继续担任审计师，有助于保持公司治理和运营的稳定，为股价提供支撑。

结论

本届股东大会顺利结束，所有议案均获一致通过，无异议。建议股东后续关注公司新股发行动态及董事会、管理层的相关经营表现。

免责声明

本文仅供参考，不构成投资建议。投资者应自行进行研究，并在做出投资决策前咨询专业顾问。

View Pharmesis Intl Historical chart here